Arcturus therapeutics to report third quarter 2020 financial results and provide corporate update on nov 9, 2020
San diego--(business wire)--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a leading clinical-stage messenger rna medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and nine months ended sept 30, 2020 after the market close on nov 9 and will also provide a corporate overview and financial results by hosting a conference call and webcast at 4:30 pm eastern time on monday, nov 9, 2020. monday, nov 9th @ 4:30 p.m. et domestic: 877-407-0784 international: 201-689-8560 conference id: 13712208 webcast: http://public.viavid.com/index.php?id=142081 about arcturus therapeutics founded in 2013 and based in san diego, california, arcturus therapeutics holdings inc. (nasdaq: arct) is a clinical-stage mrna medicines and vaccines company with enabling technologies: (i) lunar® lipid-mediated delivery, (ii) starr™ mrna technology and (iii) mrna drug substance along with drug product manufacturing expertise. arcturus’ diverse pipeline of rna therapeutic and vaccine candidates includes self-replicating mrna vaccine programs for sars-cov-2 (covid-19) and influenza, and other programs to potentially treat ornithine transcarbamylase (otc) deficiency, cystic fibrosis, cardiovascular disease along with partnered programs including glycogen storage disease type 3, hepatitis b virus, and non-alcoholic steatohepatitis (nash). arcturus’ versatile rna therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger rna, small interfering rna, replicon rna, antisense rna, microrna, dna, and gene editing therapeutics. arcturus’ technologies are covered by its extensive patent portfolio (200 patents and patent applications, issued in the u.s., europe, japan, china and other countries). arcturus’ commitment to the development of novel rna therapeutics has led to collaborations with janssen pharmaceuticals, inc., part of the janssen pharmaceutical companies of johnson & johnson, ultragenyx pharmaceutical, inc., takeda pharmaceutical company limited, curevac ag, synthetic genomics inc., duke-nus, and the cystic fibrosis foundation. for more information visit www.arcturusrx.com. in addition, please connect with us on twitter and linkedin.
